<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">medsovet</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинский Совет</journal-title><trans-title-group xml:lang="en"><trans-title>Meditsinskiy sovet = Medical Council</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2079-701X</issn><issn pub-type="epub">2658-5790</issn><publisher><publisher-name>REMEDIUM GROUP Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.21518/2079-701X-2020-17-50-55</article-id><article-id custom-type="elpub" pub-id-type="custom">medsovet-5876</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Актуальная проблема</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Actual problem</subject></subj-group></article-categories><title-group><article-title>Возможности клинического применения современных небулайзеров</article-title><trans-title-group xml:lang="en"><trans-title>Рossibilities of clinical application of modern nebulizers</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1224-1904</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Белоцерковская</surname><given-names>Ю. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Belotserkovskaya</surname><given-names>Yu. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Белоцерковская Юлия Геннадьевна, кандидат медицинских наук, доцент кафедры пульмонологии</p><p>2/1, Bldg. 1, Barrikadnaya St., Moscow, 125993</p></bio><bio xml:lang="en"><p>Yulia G. Belotserkovskaya, Cand. of Sci. (Med.), Associate Professor, Department of Pulmonology</p><p>2/1, Bldg. 1, Barrikadnaya St., Moscow, 125993</p></bio><email xlink:type="simple">belo-yuliya@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Российская медицинская академия непрерывного профессионального образования</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Russian Medical Academy of Continuous Professional Education</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2020</year></pub-date><pub-date pub-type="epub"><day>21</day><month>11</month><year>2020</year></pub-date><volume>0</volume><issue>17</issue><fpage>50</fpage><lpage>55</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Белоцерковская Ю.Г., 2020</copyright-statement><copyright-year>2020</copyright-year><copyright-holder xml:lang="ru">Белоцерковская Ю.Г.</copyright-holder><copyright-holder xml:lang="en">Belotserkovskaya Y.G.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.med-sovet.pro/jour/article/view/5876">https://www.med-sovet.pro/jour/article/view/5876</self-uri><abstract><p>Простота преобразования лекарственных растворов и суспензий в аэрозоли с использованием сжатого воздуха, вибрации пьезоэлемента или сетчатой мембраны, удобная доставка в бронхи позволяют небулайзерам занимать достойное место в лечении госпитализированных и амбулаторных больных. Различные типы небулайзеров доступны для применения в домашних условиях и в медицинских учреждениях (струйные, ультразвуковые, мембранные), и исследования показывают, что производительность и характеристики аэрозоля варьируются между разными устройствами и производителями. Струйные небулайзеры по-прежнему остаются наиболее используемыми устройствами, не требующими координации вдоха и доставки аэрозоля в дыхательные пути. Для уменьшения расхода лекарственного аэрозоля и оптимизации воздушного потока усовершенствуются технологии виртуальных клапанов (virtual valve technology (V.V.T.)), создаются струйные небулайзеры, приводимые в действие дыханием. Преимуществом небулайзерной терапии является возможность применять большие дозы лекарственных препаратов, использовать вещества, которые существуют только в ингаляционной форме. Выбор падает на небулайзер в тех случаях, когда пациент не может использовать другие устройства доставки, например при неспособности координировать вдох и поступление препарата в дыхательные пути, при тяжелом обострении бронхообструктивного заболевания, при наличии двигательных расстройств. Оптимальным устройством доставки для детей любого возраста, включая новорожденных, является небулайзер. Наиболее распространенным показанием для небулайзерной терапии является доставка бронхолитиков и ингаляционных кортикостероидов при бронхиальной астме или хронической обструктивной болезни легких, а также лечение патологии верхних дыхательных путей, в частности крупа у детей. Важное место отводится небулайзерам при необходимости назначения некоторых мукоактивных препаратов и антибиотиков. В терапии неотложных состояний может потребоваться ингаляционное введение препаратов, включая ситуации, когда пациент находится на искусственной вентиляции легких или ему установлена трахеостома. Изучается значение небулайзеров в лечении муковисцидоза, легочной артериальной гипертензии, недостаточности альфа-1-антитрипсина. Оцениваются возможности эндобронхиальной доставки гепарина, инсулина, моноклональных антител.</p></abstract><trans-abstract xml:lang="en"><p>The simplicity of converting medicinal solutions and suspensions into aerosols using mechanical and thermal energy, convenient delivery to the airways allows nebulizers to take a worthy place in the treatment of hospitalized and outpatient patients. Different types of nebulizers are available for use in the home and in medical settings (jet, ultrasound, membrane), and researches show that the performance and characteristics of the aerosol vary between different devices and manufacturers. Jet nebulizers are still the most used devices that do not require coordination of inhale and delivery of aerosol to the respiratory tract. To reduce the consumption of medicinal aerosol and optimize the air flow, virtual valve technology (V.V.T.) is being improved, and breath-actuated nebulizers are being created. The advantage of nebulizer therapy is the ability to apply large doses of medications, use substances that exist only in inhaled form. The choice falls on the nebulizer in cases where the patient can not use other delivery devices, for example, if the patient is unable to coordinate the inhalation and intake of the drug into the respiratory tract, with a severe exacerbation of obstructive disease, in the presence of motor disorders. The optimal delivery device for children of any age, including newborns, is a nebulizer. The most common indication for nebulizer therapy is the delivery of bronchodilators and inhaled corticosteroids for asthma or chronic obstructive pulmonary disease, as well as the treatment of upper respiratory tract diseases, in particular croup in children. An important place is given to nebulizers when it is necessary to prescribe certain mucolytics and antibiotics. In the treatment of emergency conditions, inhalation administration of drugs may be required, including situations when the patient is on mechanical ventilation or has a tracheostomy installed. The significance of nebulizers in the treatment of cystic fibrosis, pulmonary arterial hypertension, and alpha-1-antitrypsin deficiency is being studied. The possibilities of endobronchial delivery of heparin, insulin, and monoclonal antibodies are evaluated.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>ингаляционная терапия</kwd><kwd>респираторные заболевания</kwd><kwd>струйный небулайзер</kwd><kwd>ультразвуковой небулайзер</kwd><kwd>меш-небулайзер</kwd><kwd>клиническое применение</kwd></kwd-group><kwd-group xml:lang="en"><kwd>inhalation therapy</kwd><kwd>respiratory diseases</kwd><kwd>jet nebulizers</kwd><kwd>ultrasonic nebulizers</kwd><kwd>mesh ebulizers</kwd><kwd>clinical application</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Dhand R., Cavanaugh T., Skolnik N. Considerations for Optimal Inhaler Device Selection in Chronic Obstructive Pulmonary Disease. Cleve Clin J Med. 2018;85(2 suppl 1)19–27. doi: 10.3949/ccjm.85.s1.04.</mixed-citation><mixed-citation xml:lang="en">Dhand R., Cavanaugh T., Skolnik N. Considerations for Optimal Inhaler Device Selection in Chronic Obstructive Pulmonary Disease. Cleve Clin J Med. 2018;85(2 suppl 1)19–27. doi: 10.3949/ccjm.85.s1.04.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Roy A., Pleasants R.A., Hess D.R. Aerosol Delivery Devices for Obstructive Lung Diseases. Respir Care 2018;63(6):708–733. doi: 10.4187/respcare.06290.</mixed-citation><mixed-citation xml:lang="en">Roy A., Pleasants R.A., Hess D.R. Aerosol Delivery Devices for Obstructive Lung Diseases. Respir Care 2018;63(6):708–733. doi: 10.4187/respcare.06290.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Boe J., Dennis J.H., O’Driscoll B.R., Bauer T.T., Carone M., Dautzenberg B. et al. European Respiratory Society Guidelines on the use of nebulizers. Eur Respir J. 2001;18(1):228–242. doi: 10.1183/09031936.01.00220001.</mixed-citation><mixed-citation xml:lang="en">Boe J., Dennis J.H., O’Driscoll B.R., Bauer T.T., Carone M., Dautzenberg B. et al. European Respiratory Society Guidelines on the use of nebulizers. Eur Respir J. 2001;18(1):228–242. doi: 10.1183/09031936.01.00220001.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Hess D.R. Nebulizers: principles and performance. Respir Care. 2000:45:609–622. Available at: https://www.researchgate.net/publication/12425670_Nebulizers_Principles_and_performance.</mixed-citation><mixed-citation xml:lang="en">Hess D.R. Nebulizers: principles and performance. Respir Care. 2000:45:609–622. Available at: https://www.researchgate.net/publication/12425670_Nebulizers_Principles_and_performance.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Edge R., Butcher R. Vibrating Mesh Nebulizers for Patients with Respiratory Conditions: Clinical Effectiveness, Cost-Effectiveness, and Guidelines. Ottawa: CADTH; 2019. 20 p. Available at: https://www.ncbi.nlm.nih.gov/books/NBK546785/pdf/Bookshelf_NBK546785.pdf.</mixed-citation><mixed-citation xml:lang="en">Edge R., Butcher R. Vibrating Mesh Nebulizers for Patients with Respiratory Conditions: Clinical Effectiveness, Cost-Effectiveness, and Guidelines. Ottawa: CADTH; 2019. 20 p. Available at: https://www.ncbi.nlm.nih.gov/books/NBK546785/pdf/Bookshelf_NBK546785.pdf.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Gowda A.A., Cuccia A.D., Smaldone G.C. Reliability of Vibrating Mesh Technology. Respir Care. 2017;62(1):65–69. doi: 10.4187/respcare.04702.</mixed-citation><mixed-citation xml:lang="en">Gowda A.A., Cuccia A.D., Smaldone G.C. Reliability of Vibrating Mesh Technology. Respir Care. 2017;62(1):65–69. doi: 10.4187/respcare.04702.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Skaria S., Smaldone G.C. Omron NE U22: comparison between vibrating mesh and jet nebulizer. J Aerosol Med Pulm Drug Deliv. 2010;23(3):173– 180. doi: 10.1089/jamp.2010.0817.</mixed-citation><mixed-citation xml:lang="en">Skaria S., Smaldone G.C. Omron NE U22: comparison between vibrating mesh and jet nebulizer. J Aerosol Med Pulm Drug Deliv. 2010;23(3):173– 180. doi: 10.1089/jamp.2010.0817.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Dhand R. Nebulisers that use a vibrating mesh or plate with multiple apertures to generate aerosol. Respir Care. 2002;47(12):1406–1416. Available at: http://www.rcjournal.com/contents/12.02/12.02.1406.pdf.</mixed-citation><mixed-citation xml:lang="en">Dhand R. Nebulisers that use a vibrating mesh or plate with multiple apertures to generate aerosol. Respir Care. 2002;47(12):1406–1416. Available at: http://www.rcjournal.com/contents/12.02/12.02.1406.pdf.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Coates A.L., Green M., Leung K., Chan J., Ribeiro N., Ratjen F., Charron M. A comparison of amount and speed of deposition between the PARI LC STAR® jet nebulizer and an investigational eFlow® nebulizer. J Aerosol Med Pulm Drug Deliv. 2011;24(3):157–163. doi: 10.1089/jamp.2010.0861.</mixed-citation><mixed-citation xml:lang="en">Coates A.L., Green M., Leung K., Chan J., Ribeiro N., Ratjen F., Charron M. A comparison of amount and speed of deposition between the PARI LC STAR® jet nebulizer and an investigational eFlow® nebulizer. J Aerosol Med Pulm Drug Deliv. 2011;24(3):157–163. doi: 10.1089/jamp.2010.0861.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Княжеская Н.П. Особенности использования небулайзеров в терапии хронических заболеваний легких. РМЖ. 2017;(18):1317–1320. Режим доступа: https://www.rmj.ru/articles/bolezni_dykhatelnykh_putey/Osobennosti_ispolyzovaniya_nebulayzerov_v_terapii_hronicheskih_zabolevaniy_legkih/#ixzz6aBFT7T4h.</mixed-citation><mixed-citation xml:lang="en">Knyazheskaya N.P. Features of the use of nebulizers in the therapy of chronic lung diseases. RMZH = RMJ. 2017;(18):1317–1320 (In Russ.) Available at: https://www.rmj.ru/articles/bolezni_dykhatelnykh_putey/Osobennosti_ispolyzovaniya_nebulayzerov_v_terapii_hronicheskih_zabolevaniy_legkih/#ixzz6aBFT7T4h.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Hess D.R. Aerosol delivery devices in the treatment of asthma. Respir Care. 2008;53(6):699–723. Available at: https://pubmed.ncbi.nlm.nih.gov/18501026/.</mixed-citation><mixed-citation xml:lang="en">Hess D.R. Aerosol delivery devices in the treatment of asthma. Respir Care. 2008;53(6):699–723. Available at: https://pubmed.ncbi.nlm.nih.gov/18501026/.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Lavorini F., Fontana G.A., Usmani O.S. New Inhaler Devices – The Good, the Bad and the Ugly. Respiration. 2014;88(1):3–15. doi: 10.1159/000363390.</mixed-citation><mixed-citation xml:lang="en">Lavorini F., Fontana G.A., Usmani O.S. New Inhaler Devices – The Good, the Bad and the Ugly. Respiration. 2014;88(1):3–15. doi: 10.1159/000363390.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">O’Callaghan C., Barry P.W. The science of nebulised drug delivery. Thorax. 1997;52(2):31–44. doi: 10.1136/thx.52.2008.s31.</mixed-citation><mixed-citation xml:lang="en">O’Callaghan C., Barry P.W. The science of nebulised drug delivery. Thorax. 1997;52(2):31–44. doi: 10.1136/thx.52.2008.s31.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Локшина Э.Э., Зайцева О.В. Ингаляционная терапия у детей: новые возможности. Пульмонология. 2019;29(4):499–507. doi: 10.18093/0869-0189-2019-29-4-499-507.</mixed-citation><mixed-citation xml:lang="en">Lokshina Е.Е., Zaytseva О.V. Inhalation therapy in children: new opportunities. P’monologiya = Pulmonology. 2019;29(4):499–507. (In Russ.) doi: 10.18093/0869-0189-2019-29-4-499-507.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Melani A.S. Nebulized corticosteroids in asthma and COPD. An Italian appraisal. Respir Care. 2012;57(7):1161–1174. Available at: http://rc.rcjournal.com/content/57/7/1161.</mixed-citation><mixed-citation xml:lang="en">Melani A.S. Nebulized corticosteroids in asthma and COPD. An Italian appraisal. Respir Care. 2012;57(7):1161–1174. Available at: http://rc.rcjournal.com/content/57/7/1161.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Chrystyn H., van der Palen J., Sharma R., Barnes N., Delafont B., Mahajan A., Thomas M. Device errors in asthma and COPD: systematic literature review and meta-analysis. NPJ Prim Care Respir Med. 2017;27(1):22. doi: 10.1038/s41533-017-0016-z.</mixed-citation><mixed-citation xml:lang="en">Chrystyn H., van der Palen J., Sharma R., Barnes N., Delafont B., Mahajan A., Thomas M. Device errors in asthma and COPD: systematic literature review and meta-analysis. NPJ Prim Care Respir Med. 2017;27(1):22. doi: 10.1038/s41533-017-0016-z.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Dhand R., Dolovich M., Chipps B., Myers T.R., Restrepo R., Farrar J.R. The role of nebulized therapy in the management of COPD: evidence and recommendations. COPD. 2012;9(1):58–72. doi: 10.3109/15412555.2011.630047.</mixed-citation><mixed-citation xml:lang="en">Dhand R., Dolovich M., Chipps B., Myers T.R., Restrepo R., Farrar J.R. The role of nebulized therapy in the management of COPD: evidence and recommendations. COPD. 2012;9(1):58–72. doi: 10.3109/15412555.2011.630047.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Ari A., Fink J.B., Dhand R. Inhalation therapy in patients receiving mechanical ventilation: an update. J Aerosol Med Pulm Drug Deliv. 2012;25(6):319– 332. doi: 10.1089/jamp.2011.0936.</mixed-citation><mixed-citation xml:lang="en">Ari A., Fink J.B., Dhand R. Inhalation therapy in patients receiving mechanical ventilation: an update. J Aerosol Med Pulm Drug Deliv. 2012;25(6):319– 332. doi: 10.1089/jamp.2011.0936.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Dhand R. How should aerosols be delivered during invasive mechanical ventilation? Respir Care. 2017;62(10):1343–1367. doi: 10.4187/respcare.05803.</mixed-citation><mixed-citation xml:lang="en">Dhand R. How should aerosols be delivered during invasive mechanical ventilation? Respir Care. 2017;62(10):1343–1367. doi: 10.4187/respcare.05803.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Hess D.R. Aerosol therapy during noninvasive ventilation or high- flow nasal cannula. Respir Care. 2015;60(6):880–891. doi: 10.4187/respcare.04042.</mixed-citation><mixed-citation xml:lang="en">Hess D.R. Aerosol therapy during noninvasive ventilation or high- flow nasal cannula. Respir Care. 2015;60(6):880–891. doi: 10.4187/respcare.04042.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Berlinski A., Ari A., Davies P., Fink J., Majaesic C., Reychler G. et al. Workshop report: aerosol delivery to spontaneously breathing tracheostomized patients. J Aerosol Med Pulm Drug Deliv. 2017;30(4):207–222. doi: 10.1089/jamp.2016.1348.</mixed-citation><mixed-citation xml:lang="en">Berlinski A., Ari A., Davies P., Fink J., Majaesic C., Reychler G. et al. Workshop report: aerosol delivery to spontaneously breathing tracheostomized patients. J Aerosol Med Pulm Drug Deliv. 2017;30(4):207–222. doi: 10.1089/jamp.2016.1348.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Girbes A.R., Beishuizen A., Strack van Schijndel R.J. Pharmacological treatment of sepsis. Fundam Clin Pharmacol. 2008;22(4):355–361. doi: 10.1111/j.1472-8206.2008.00606.x.</mixed-citation><mixed-citation xml:lang="en">Girbes A.R., Beishuizen A., Strack van Schijndel R.J. Pharmacological treatment of sepsis. Fundam Clin Pharmacol. 2008;22(4):355–361. doi: 10.1111/j.1472-8206.2008.00606.x.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Sun Y., Yang R., Zhong J.G., Fang F., Jiang J.J., Liu MY., Lu J. Aerosolised surfactant generated by a novel noninvasive apparatus reduced acute lung injury in rats. Crit Care. 2009;13(2):R31. doi: 10.1186/cc7737.</mixed-citation><mixed-citation xml:lang="en">Sun Y., Yang R., Zhong J.G., Fang F., Jiang J.J., Liu MY., Lu J. Aerosolised surfactant generated by a novel noninvasive apparatus reduced acute lung injury in rats. Crit Care. 2009;13(2):R31. doi: 10.1186/cc7737.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Mohamed H.S., Meguid M.M. Effect of nebulized budesonide on respiratory mechanics and oxygenation in acute lung injury/acute respiratory distress syndrome: Randomized controlled study. Saudi J Anaesth. 2017;11(1):9–14. doi: 10.4103/1658-354X.197369.</mixed-citation><mixed-citation xml:lang="en">Mohamed H.S., Meguid M.M. Effect of nebulized budesonide on respiratory mechanics and oxygenation in acute lung injury/acute respiratory distress syndrome: Randomized controlled study. Saudi J Anaesth. 2017;11(1):9–14. doi: 10.4103/1658-354X.197369.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">McAuley D.F., Laffey J.G., O’Kane C.M., Perkins G.D., Mullan B., Trinder T.J. et al. Simvastatin in the acute respiratory distress syndrome. N Engl J Med. 2014;371(18):1695–1703. doi: 10.1056/NEJMoa1403285.</mixed-citation><mixed-citation xml:lang="en">McAuley D.F., Laffey J.G., O’Kane C.M., Perkins G.D., Mullan B., Trinder T.J. et al. Simvastatin in the acute respiratory distress syndrome. N Engl J Med. 2014;371(18):1695–1703. doi: 10.1056/NEJMoa1403285.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Hill N.S., Preston I.R., Roberts K.E. Inhaled Therapies for Pulmonary Hypertension. Respir Care. 2015;60(6):794–802. doi: 10.4187/respcare.03927.</mixed-citation><mixed-citation xml:lang="en">Hill N.S., Preston I.R., Roberts K.E. Inhaled Therapies for Pulmonary Hypertension. Respir Care. 2015;60(6):794–802. doi: 10.4187/respcare.03927.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Wang S., Yu M., Zheng X., Dong S.A. Bayesian network meta-analysis on the efficacy and safety of eighteen targeted drugs or drug combinations for pulmonary arterial hypertension. Drug Deliv. 2018;25(1):1898–1909. doi: 10.1080/10717544.2018.1523257.</mixed-citation><mixed-citation xml:lang="en">Wang S., Yu M., Zheng X., Dong S.A. Bayesian network meta-analysis on the efficacy and safety of eighteen targeted drugs or drug combinations for pulmonary arterial hypertension. Drug Deliv. 2018;25(1):1898–1909. doi: 10.1080/10717544.2018.1523257.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Castellani C., Duff A.J.A., Bell S.C., Heijerman H.G.M., Munck A., Ratjen F. et al. ECFS best practice guidelines: The 2018 revision. J Cyst Fibros. 2018;17(2):153–178. doi: 10.1016/j.jcf.2018.02.006.</mixed-citation><mixed-citation xml:lang="en">Castellani C., Duff A.J.A., Bell S.C., Heijerman H.G.M., Munck A., Ratjen F. et al. ECFS best practice guidelines: The 2018 revision. J Cyst Fibros. 2018;17(2):153–178. doi: 10.1016/j.jcf.2018.02.006.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Hill A.T., Sullivan A.L., Chalmers J.D., De Soyza A., Elborn J.S., Floto R.A. et al. British Thoracic Society guideline for bronchiectasis in adults. BMJ Open Respir Res. 2018;5:e000348. doi: 10.1136/bmjresp-2018-000348.</mixed-citation><mixed-citation xml:lang="en">Hill A.T., Sullivan A.L., Chalmers J.D., De Soyza A., Elborn J.S., Floto R.A. et al. British Thoracic Society guideline for bronchiectasis in adults. BMJ Open Respir Res. 2018;5:e000348. doi: 10.1136/bmjresp-2018-000348.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Abdellatif S., Trifi A., Daly F., Mahjoub K., Nasri R., Ben Lakhal S. Efficacy and toxicity of aerosolised colistin in ventilator-associated pneumonia: A prospective, randomised trial. Ann Intensive Care. 2016;6(1):26. doi: 10.1186/s13613-016-0127-7.</mixed-citation><mixed-citation xml:lang="en">Abdellatif S., Trifi A., Daly F., Mahjoub K., Nasri R., Ben Lakhal S. Efficacy and toxicity of aerosolised colistin in ventilator-associated pneumonia: A prospective, randomised trial. Ann Intensive Care. 2016;6(1):26. doi: 10.1186/s13613-016-0127-7.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Banerjee S., McCormack S. Acetylcysteine for Patients Requiring Mucous Secretion Clearance: A Review of Clinical Effectiveness and Safety. Ottawa: CADTH; 2019. 22 p. Available at: https://www.ncbi.nlm.nih.gov/books/NBK546019/pdf/Bookshelf_NBK546019.pdf.</mixed-citation><mixed-citation xml:lang="en">Banerjee S., McCormack S. Acetylcysteine for Patients Requiring Mucous Secretion Clearance: A Review of Clinical Effectiveness and Safety. Ottawa: CADTH; 2019. 22 p. Available at: https://www.ncbi.nlm.nih.gov/books/NBK546019/pdf/Bookshelf_NBK546019.pdf.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Yang C., Montgomery M. Dornase alfa for cystic fibrosis. Cochrane Database Syst Rev. 2018;9(9):CD001127. doi: 10.1002/14651858.CD001127.pub4.</mixed-citation><mixed-citation xml:lang="en">Yang C., Montgomery M. Dornase alfa for cystic fibrosis. Cochrane Database Syst Rev. 2018;9(9):CD001127. doi: 10.1002/14651858.CD001127.pub4.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Monk R., Graves M., Williams P., Strange C. Inhaled alpha 1-antitrypsin: Gauging patient interest in a new treatment. COPD. 2013;10(4):411–415. doi: 10.3109/15412555.2012.758698.</mixed-citation><mixed-citation xml:lang="en">Monk R., Graves M., Williams P., Strange C. Inhaled alpha 1-antitrypsin: Gauging patient interest in a new treatment. COPD. 2013;10(4):411–415. doi: 10.3109/15412555.2012.758698.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Stolk J., Tov N., Chapman K.R., Fernandez P., MacNee W., Hopkinson N.S. et al. Efficacy and safety of inhaled alpha1-antitrypsin in patients with severe alpha1-antitrypsin deficiency and frequent exacerbations of COPD. Eur Respir J. 2019;54(5):1900673. doi: 10.1183/13993003.00673-2019.</mixed-citation><mixed-citation xml:lang="en">Stolk J., Tov N., Chapman K.R., Fernandez P., MacNee W., Hopkinson N.S. et al. Efficacy and safety of inhaled alpha1-antitrypsin in patients with severe alpha1-antitrypsin deficiency and frequent exacerbations of COPD. Eur Respir J. 2019;54(5):1900673. doi: 10.1183/13993003.00673-2019.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Bennett J.V., Fernandez de Castro J., Valdespino-Gomez J.L., Garcia-Garcia Mde L., Islas-Romero R., Echaniz-Aviles G. et al. Aerosolized measles and measles-rubella vaccines induce better measles antibody booster responses than injected vaccines: Randomized trials in Mexican schoolchildren. Bull World Health Organ. 2002;80(10):806–812. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2567652/pdf/12471401.pdf.</mixed-citation><mixed-citation xml:lang="en">Bennett J.V., Fernandez de Castro J., Valdespino-Gomez J.L., Garcia-Garcia Mde L., Islas-Romero R., Echaniz-Aviles G. et al. Aerosolized measles and measles-rubella vaccines induce better measles antibody booster responses than injected vaccines: Randomized trials in Mexican schoolchildren. Bull World Health Organ. 2002;80(10):806–812. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2567652/pdf/12471401.pdf.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">McCarthy S.D., González H.E., Higgins B.D. Future Trends in Nebulized Therapies for Pulmonary Disease. J Pers Med. 2020;10(2):37. doi: 10.3390/jpm10020037.</mixed-citation><mixed-citation xml:lang="en">McCarthy S.D., González H.E., Higgins B.D. Future Trends in Nebulized Therapies for Pulmonary Disease. J Pers Med. 2020;10(2):37. doi: 10.3390/jpm10020037.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Glas G.J., Serpa Neto A., Horn J., Cochran A., Dixon B., Elamin E.M. et al. Nebulized heparin for patients under mechanical ventilation: An individual patient data meta-analysis. Ann Intensive Care. 2016;6:33. doi: 10.1186/s13613-016-0138-4.</mixed-citation><mixed-citation xml:lang="en">Glas G.J., Serpa Neto A., Horn J., Cochran A., Dixon B., Elamin E.M. et al. Nebulized heparin for patients under mechanical ventilation: An individual patient data meta-analysis. Ann Intensive Care. 2016;6:33. doi: 10.1186/s13613-016-0138-4.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Respaud R., Marchand D., Parent C., Pelat T., Thullier P., Tournamille J.F. et al. Effect of formulation on the stability and aerosol performance of a nebulized antibody. Mabs. 2014;6:1347–1355. doi: 10.4161/mabs.29938.</mixed-citation><mixed-citation xml:lang="en">Respaud R., Marchand D., Parent C., Pelat T., Thullier P., Tournamille J.F. et al. Effect of formulation on the stability and aerosol performance of a nebulized antibody. Mabs. 2014;6:1347–1355. doi: 10.4161/mabs.29938.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Fan W., Nakazawa K., Abe S., Inoue M., Kitagawa M., Nagahara N., Makita K. Inhaled aerosolized insulin ameliorates hyperglycemia-induced inflammatory responses in the lungs in an experimental model of acute lung injury. Crit Care. 2013;17(2):R83. doi: 10.1186/cc12697.</mixed-citation><mixed-citation xml:lang="en">Fan W., Nakazawa K., Abe S., Inoue M., Kitagawa M., Nagahara N., Makita K. Inhaled aerosolized insulin ameliorates hyperglycemia-induced inflammatory responses in the lungs in an experimental model of acute lung injury. Crit Care. 2013;17(2):R83. doi: 10.1186/cc12697.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Standaert T.A., Morlin G.L., Williams-Warren J., Joy P., Pepe M.S., Weber A. et al. Effects of repetitive use and cleaning techniques of disposable jet nebulizers on aerosol generation. Chest. 1998;114(2):577–586. doi: 10.1378/chest.114.2.577.</mixed-citation><mixed-citation xml:lang="en">Standaert T.A., Morlin G.L., Williams-Warren J., Joy P., Pepe M.S., Weber A. et al. Effects of repetitive use and cleaning techniques of disposable jet nebulizers on aerosol generation. Chest. 1998;114(2):577–586. doi: 10.1378/chest.114.2.577.</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Alexander L., Carson J., McCaughan J., Moore J.E., Millar B.C. Thinking inside the box: nebulizer care, safe storage, and risk of infection in cystic fibrosis. J Bras Pneumol. 2020;46(2):e20190226. doi: 10.36416/1806-3756/e20190226.</mixed-citation><mixed-citation xml:lang="en">Alexander L., Carson J., McCaughan J., Moore J.E., Millar B.C. Thinking inside the box: nebulizer care, safe storage, and risk of infection in cystic fibrosis. J Bras Pneumol. 2020;46(2):e20190226. doi: 10.36416/1806-3756/e20190226.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
